Shawn Charles
About Shawn Charles
Shawn Charles is an Operations Analyst and Consultant in Finance & Resource Operations at Bristol Myers Squibb and a Clinical Bioanalytical Scientific Monitor at ICON plc, with extensive experience in bioanalytical and pharmaceutical research.
Current Positions at ICON plc and Bristol Myers Squibb
Shawn Charles is currently employed at ICON plc as a Clinical Bioanalytical Scientific Monitor, based in New Jersey, United States. In addition, he works as an Operations Analyst, Consultant, Finance & Resource Operations, Global Outsourcing Management at Bristol Myers Squibb in Lawrenceville, NJ, United States.
Previous Roles at Sanofi, Celgene, Merck, and Intervet/Schering-Plough Animal Health
Shawn Charles' prior work experiences include being a Bioanalytical Outsourcing Manager at Sanofi from 2020 to 2021 in Bridgewater, New Jersey, and a Reference Standard Coordinator at Celgene from 2019 to 2020 in Summit, NJ. He was also a Scientist at Merck Research Laboratories for nine years (2010-2019) in Rahway and a Scientist 2 at Intervet/Schering-Plough Animal Health for an impressive ten years (2000-2010).
Educational Background in Animal Science
Shawn Charles received his Master of Science (MS) in Animal Science from the University of Tennessee, Knoxville. He also holds a Bachelor of Science (BS) in Animal Science with a Minor in Business from Delaware Valley College.
Software and Efficiency Implementations
Shawn Charles has made significant contributions in his field by developing a universal laboratory robotic instrumentation software program for liquid handler (Hamilton), which increased precision, accuracy, and productivity by 50% for the entire department. He also implemented an automated report writing tool to extract data from Watson LIMS to Microsoft Word, significantly increasing the efficiency of writing and tabulating analytical reports by 75%.
Project and Program Management Responsibilities
Charles has been responsible for designing and supporting pharmacokinetic, metabolism (ADME), and residue programs to support the registration of small molecule pharmaceuticals for studies both in-house and with external providers. He managed multiple projects and delivered data on time, playing a crucial role in drug discovery, nonclinical, clinical, and toxicology studies.